Overcome tumor relapse in CAR T cell therapy.
Clin Transl Oncol
; 24(10): 1833-1843, 2022 Oct.
Article
en En
| MEDLINE
| ID: mdl-35678948
ABSTRACT
Chimeric antigen receptor (CAR) T cell therapy is a novel therapeutic approach that uses gene editing techniques and lentiviral transduction to engineer T cells so that they can effectively kill tumors. However, CAR T cell therapy still has some drawbacks many patients who received CAR T cell therapy and achieve remission, still had tumor relapse and treatment resistance, which may be due to tumor immune escape and CAR T cell dysfunction. To overcome tumor relapse, more researches are being done to optimize CAR T cell therapy to make it more precise and personalized, including screening for more specific tumor antigens, developing novel CAR T cells, and combinatorial treatment approaches. In this review, we will discuss the mechanisms as well as the progress of research on overcoming plans.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Inmunoterapia Adoptiva
/
Neoplasias
Límite:
Humans
Idioma:
En
Revista:
Clin Transl Oncol
Año:
2022
Tipo del documento:
Article
País de afiliación:
China